1 Validation of the International IgA risk prediction tool in American Indians and Hispanics.

2 Authors

3	1. Saeed Kamran Shaffi. MD, MS*					
4	Staff Nephrologist, Raymond G. Murphy VA Medical Center					
5	Associate Professor, Department of Internal Medicine, Division of Nephrology,					
6	University of New Mexico					
7						
8	2. Edger Fischer, M.D., Ph.D.∞					
9	Professor of Pathology					
10	Division of Surgical Pathology and Cytopathology					
11	University of New Mexico					
12						
13	Christos Argyropoulos, MD, Ph.D., FASN[^]					
14	Associate Professor, Department of Internal Medicine, Division of Nephrology,					
15	University of New Mexico					
16						
17	4. Brent Wagner, MD*					
18	Director, Kidney Institute of New Mexico					
19	University of New Mexico Health Sciences Center					
20	ACOS, Research Service					
21	New Mexico VA Health Care System*					
22						
23	*Raymond G. Murphy New Mexico VA Health Care System					
24	1501 San Pedro Dr SE, Albuquerque, NM, 87108					
25						
26	∞Department of Pathology					
27	1 University of New Mexico					
28	MSC08 4640					
29	Albuquerque, NM, 87106					
30						
31	^Division of Nephrology,					
32	1 University of New Mexico					
33	MSC 04-2785					
34	Albuquerque, NM, 87131					
35						
36	Corresponding author: Saeed Kamran Shaffi,					

37 Email: kshaffi@salud.unm.edu

38 Abstract

39	Background: The International Immunoglobulin A nephropathy (IgAN) risk prediction assesses							
40	the risk of kidney failure in patients with IgAN. The performance of this risk prediction tool has							
41	not been studied in American Indians and Hispanics. We conducted a single-center study to							
42	assess the equation performance in this population.							
43								
44	Methods: We calculated the 5-year risk of developing kidney failure with the IgAN risk							
45	prediction equation without race and assessed the equation performance using the metrics of							
46	calibration, discrimination, and overall prediction error.							
47								
48	Results: Thirty-four patients were included, most of whom identified as of Hispanic							
49	race/ethnicity (44.1%), or as American Indians (26.5%). At biopsy, the median (IQR) age, serum							
50	creatinine, and spot urine protein to creatinine ratio were 38 years (27-45), 2.15 mg/dl (1.51-							
51	3.04), and 2.7 g/g (1.5-5.8), respectively. The equation identified patients at high risk of							
52	developing kidney failure early with a concordance statistic of 0.79 (95% CI 0.68 – 0.89). The							
53	agreement between observed and predicted outcomes at 5 years was marginal, with over-							
54	estimation of risk for patients with low observed risk and vice versa. Overall prediction error							
55	was suboptimal in this cohort [index of prediction accuracy 0.34 (0.03 – 0.51)].							
56								
57	Conclusions: The International IgAN risk prediction equation without race accurately identified							
58	patients at elevated risk of developing kidney failure. At 5 years, the agreement between the							

- 59 observed and predicted outcomes was sub-optimal, possibly due to advanced kidney disease in
- 60 this cohort. A diverse development population may improve the risk prediction.

- 62 Key words: Immunoglobulin A Risk Prediction Risk Prediction Model Calibration Assessment Risk
- 63 Prediction Model Discrimination Assessment

64 Introduction:

65 IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide, with an 66 incidence of 2.5 per 100,000 in adults. It is associated with end-stage kidney disease (ESKD) in 10-40% of 67 patients by ten years of diagnosis [1]. Our understanding of IgAN pathophysiology has improved due to 68 recent advances, which have led to new therapies [2, 3]. Therefore, it is imperative to identify patients 69 who would rapidly progress to kidney failure and would benefit from early goal-directed treatments. 70 Furthermore, an accurate risk prediction tool - that identifies patients at an elevated risk of developing 71 kidney failure - would assist patients and clinicians to prepare for transplant and renal replacement 72 therapy and instituting measures to decrease cardiovascular risk, which is associated with mortality in 73 patients with chronic kidney disease [4]. 74 To address these issues, Barbour et al. developed an International IgA risk prediction tool that uses 75 demographic, clinical, and kidney biopsy variables to assess the risk of kidney failure or >50% decline in 76 the estimated glomerular filtration rate (eGFR) [5]. The authors developed two equations with and 77 without an ethnic variable (Chinese, Japanese, or Other). The equation without a race/ethnicity variable 78 was developed (n = 2781) and validated (n = 1146) in large cohorts comprising Europeans, Chinese, and 79 Japanese. Since the publication of the original report, IgAN risk prediction tool performance has been 80 studied in Chinese [6, 7], South Asian [8], Greek [9], and South American [7] cohorts. Table 2 summarizes 81 the performance of the equation without the race/ethnicity variable in these cohorts. The equation 82 performance has not been studied in the Hispanic and American Indian populations. A New Mexico 83 based kidney biopsy registry data analysis has revealed a higher frequency of IgAN in the American 84 Indians compared to their state population share which may point towards a higher incidence of IgAN in 85 them [10]. Therefore, we conducted this single-center study to assess the performance of the 86 International IgA risk prediction tool without race in a cohort from New Mexico where, Hispanics and 87 American Indians are in the majority.

88

89 Methods:

90 The University of New Mexico Kidney Biopsy registry was established by searching for the current 91 procedural terminology (CPT) codes for kidney biopsies performed at the University of New Mexico 92 (UNM) hospital between 2001 and 2016. The institutional review board at UNM approved the Kidney 93 Biopsy Registry. The principal investigator (SKS) created a HIPPA complaint online Kidney Biopsy registry. 94 We queried the complete biopsy report for the following terms: "Immunoglobulin A nephropathy," "IgA Nephropathy," and "IgAN." We reviewed the biopsies to identify patients with primary IgAN who met 95 96 the inclusion criteria. The IgA risk prediction tool without the race variable uses demographic and clinical 97 variables at the time of biopsy that includes chronic kidney disease epidemiology (CKD-EPI) equation 98 estimated GFR, mean arterial blood pressure, proteinuria, age, the Oxford kidney biopsy classification 99 scores of mesangial hypercellularity, endothelial proliferation, segmental sclerosis, and tubular atrophy, 100 and medication use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, and 101 immunosuppression around the biopsy to predict the risk of kidney failure defined as: 1) end-stage kidney disease requiring dialysis or a kidney transplant or an estimated glomerular filtration rate of < 15 102 103 ml/min/ $1.73m^2$ – or, 2) >50% decline in eGFR from the baseline value. For this study, we included 104 patients with primary IgAN and on whom the International IgAN Prediction Tool without race variable 105 predictors were available. Other inclusion criteria included the availability of longitudinal data for at 106 least 12 months. The patients who developed kidney failure or had >50% decline in the eGFR within 12 107 months were also included. We excluded patients who were < 18 years of age, who had kidney failure at 108 the time of biopsy, and on whom the risk prediction variables or longitudinal laboratory data to assess 109 risk were unavailable. The primary outcome was the development of end-stage kidney disease or an 110 eGFR <15 ml/min/1.73m² or a > 50% decline in the estimated GFR from the value at the time of biopsy.

111 We summarized the baseline variables stratified on race and ethnicity and reported the categorical 112 variables as n (%) and continuous variables as median (IQR). For comparisons between groups, we 113 performed the Kruskal-Wallis Rank Sum test or Fisher's Exact test as appropriate. A renal pathologist 114 (EF) reviewed all the biopsies and assigned them a MEST-C score. For survival analysis, patients were 115 censored when they were lost to follow-up or at the end of the study. 116 We calculated the linear predictors and the predicted probability of the primary outcome using the 117 formula without the race variable (S1) as we had few patients with the Chinese or Japanese race in our 118 cohort. 119 We assessed the performance of the equation in our cohort using the metrics of calibration, 120 discrimination, and the overall prediction error [11, 12]. A well-calibrated risk assessment model's 121 predictions should match the observed outcomes. Ideally, a model's predictions should not only match 122 the observed effects at a particular time (e.g., 5 years) - known as calibration in the large - as well as 123 across the entire range of predictions. The population is usually divided into risk categories for 124 calibration assessment. The mean observed risk for each category is obtained from a Kaplan-Meyer 125 model and risk predictions from the risk equation. For each category, the observed and predicted risks 126 are plotted to assess agreement. There are a few issues with this approach; first, the risk categories are 127 arbitrary and result in loss of information, and second, this method cannot account for censored 128 patients. To circumvent these issues, we used the pseudo-observations approach for the primary 129 outcome indicator as recommended by the Strengthening Analytical Thinking of Observations Studies 130 (STRATOS) initiative[11, 12]. Observed risk calculations employed weighting techniques with pseudo-131 observations accounting for the censored patients. We regressed the primary outcome with the linear 132 predictor by performing a Cox-proportional Hazard analysis. We obtained the 5-year estimated and 133 observed risk and plotted them to obtain a calibration plot. The calibration plot should follow a 45-134 degree line for a well-calibrated equation; risk estimate values above and below the 45-degree line

135	suggest under and over-prediction, respectively. We also obtained numerical summaries of calibration.
136	The ratio of the observed and expected outcomes (O/E) should be 1; a ratio less than 1 signifies
137	overprediction and greater than 1 under-prediction. We obtained the O/E ratio at 5 years. We regressed
138	the primary outcome with the log-transformed predicted risk using a restricted cubic splines model with
139	smoothing to obtain the calibration intercept and slope. An intercept of 0 means that, on average, the
140	observed and the predicted risks are well matched. A slope greater than or less than 1 indicates the
141	homogeneity and heterogeneity of the risk estimates, respectively.
142	Discrimination assesses the ability of a risk model to identify patients who had the outcome of interest
143	earlier than others. We regressed the primary outcome with the linear predictor to assess discrimination
144	and calculated the concordance statistics (C-Statistic). The area under the curve (AUC) was graphically
145	represented by plotting the true positive rate (sensitivity) against the false positive rate (1 – specificity).
146	The index of prediction accuracy (IPA) summarizes both calibration and discrimination and represents
147	the overall prediction error [13]. We used the following formula to calculate IPA:
148	PA= 1 – Brier Score (Prediction Model) / Brier Score (Null Model)
149	Where the Brier score is the mean squared difference between the primary outcome indicator and risk
150	estimates, the prediction model is a Cox-proportional Hazards model regressed with the linear predictor,
151	and the null model had no predictors. A higher IPA score indicates better model performance.
152	We used bootstrapping approach (100 bootstraps with data replacement) for estimating the area under
153	the curve, C-statistics, and IPA to ensure that the standard errors and confidence intervals for these
154	metrics were accurate.

156 Results:

157 We identified 74 patients with suspected IgA nephropathy by searching the University of New Mexico 158 Kidney biopsy registry (Fig 1). Out of 74, 34 patients met the eligibility criteria. The median age at the 159 time of the kidney biopsy was 38 years (IQR 27- 45 years) [Table 1]. Most of the patients identified as of 160 the White race (38%). Of the patients who identified as White, the majority were of Hispanic ethnicity (53%). We collated race and ethnicity into a single variable and observed that about 3 out of 7 patients 161 162 were of Hispanic race/ethnicity (44.1%), 2 out of 7 identified as of American Indian race/non-Hispanic 163 ethnicity (26.5%), and the rest were of other races and ethnicities (29.4%). The other category included 164 Asians (n = 3), non-Hispanic Whites (n=3), African Americans (n =1), and of different races or ethnicities 165 or unknown races and ethnicities (n=3). 166 At the time of biopsy, the median (IQR) serum creatinine and Chronic Kidney Disease Epidemiology 167 equation (CKD-EPI) eGFR were 2.15 mg/dl (1.51 - 3.04) and 34 ml/min/1.73m² (20-51), respectively 168 (Table 1). Median (IQR) proteinuria assessed by a spot urine protein to creatinine ratio around the time 169 of biopsy was 2.7 g/g (1.5-5.8). Mean arterial blood pressure was 99 mm Hg (IQR 89 -104 mm Hg). Thirty-five percent of the patients were on immunosuppression, and 62% were either on an angiotensin-170 171 converting enzyme inhibitor or an angiotensin receptor blocker within 12 months of IgAN diagnosis. 172 American Indians showed a non-significant trend towards a higher serum creatinine, mean arterial 173 pressure, and a lower CKD-EPI estimated GFR than the other races. American Indians and Hispanics showed a trend towards higher proteinuria around the time of biopsy than the other races, but it was 174 175 not statistically significant. On the Oxford classification of IgAN, Hispanics were more likely (100%) to 176 have an S1 score than the other races (p 0.049). Of note, 89% of the American Indians had an S1 score 177 on kidney biopsy.

179	Figure 3 shows the plot of the 5-year estimated and observed risk. The observed risk was lower for the
180	estimated risks between 20 and 50%: therefore, the model overestimated risk. The observed risk was

- 181 higher for the estimated risks above 50%, indicating an underestimation of risk by the model; however,
- due to a small sample size, the confidence intervals were wide indicating imprecision of our findings.
- 183 Table 3 summarizes the numerical summaries of model calibration. At five years, the observed and
- estimated risk ratio (O/E) was less than 1 [0.88 (95% CI (Confidence Interval) 0.51-1.26)], indicating over-
- 185 prediction; however, the confidence intervals crossed 1. The intercept was close to 0 [0.10 (Cl 0.37 -
- 186 0.58)]; since the confidence intervals crossed 0, we cannot make a conclusive statement about the
- 187 intercept.
- 188 The risk prediction equation identified patients at a greater risk of developing the primary outcome early
- 189 with a C-statistic of 0.79 (0.68 0.89). Figure 2 shows the receiver operator curve (ROC) with the area
- 190 under the curve, which was 0.78 (0.58 -0.98).
- 191 The prediction accuracy index was 0.34 (0.03 -0.51) (table 3), which was marginal due to poor model

192 calibration in our population.

- 193 In summary, in our cohort, the international IgA risk prediction tool had less than optimal calibration;
- 194 however, there was uncertainty in our results and excellent discrimination.

196 Discussion:

197	We assessed the performance of the International IgA risk prediction tool without race in a cohort from
198	2001 to 2016, which was primarily composed of the Hispanic and American Indian populations.
199	Compared to the equation development cohort, our population had a higher baseline creatinine
200	[median (IQR); 1.0 (0.8-1.4) vs. 2.14 (1.51 - 3.04)] and proteinuria [median (IQR); 1.2 (0.7 -2.2) vs. 2.7
201	(1.5-5.8)] around the time of IgA nephropathy diagnosis [5]. These patients were more likely to have
202	higher segmental sclerosis (S1 77% vs. 88%) and tubular atrophy scores (T1 24.7 vs. 71% and T2 4.6 vs.
203	26%, respectively). Considering these findings, it is reasonable to assume that our cohort had a longer
204	disease duration and severity. Indeed, the equation derivation population was younger when diagnosed
205	with IgAN than the population in our study [Age(years); median (IQR); 35.6 (28.2 -45.4) vs. 38 (27-45)]. In
206	our population, Hispanics were more likely to have segmental sclerosis on kidney biopsy (p 0.049) [Table
207	1]. For these reasons, the probability of achieving the primary outcome was higher in our cohort (68%)
208	than in the equation development cohort (17.7%). All these findings may be explained by healthcare
209	disparities faced by the Hispanic and American Indian residents of New Mexico. Race and ethnicity often
210	provide insight into the socioeconomic and healthcare disparities in a population [14]. A review of the
211	U.S. census 2017 data shows that in New Mexico, the poverty rates were higher for Hispanics (24.1 %)
212	and American Indians (31.9%) than for Whites (17.7%) or Asians (10.5%) [15]. Furthermore, for each
213	dollar earned by the White/Non-Hispanic residents of New Mexico, the American Indians and Hispanics
214	earned approximately one-third less, highlighting the earnings disparities [16].
215	This study confirms the results of a previous study [10] looking at the frequency of IgAN in New Mexico
216	in various races. US census data from 2010 showed that White/non-Hispanic, Hispanic, and American
217	Indian shares of New Mexico's population were 40.6, 46.4, and 8.5%, respectively [17]. The proportion
218	of the Hispanics in our dataset (44%) matched their state population share; however, American Indians'

219 representation in our cohort was more than expected (26%) which may point towards a higher

220 incidence of IgAN in the American Indian. This trend should be systematically evaluated in larger

datasets.

A good prediction equation should be able to distinguish patients who are at low risk of achieving an

223 outcome of interest from those who are at elevated risk. The international IgAN risk prediction tool did

an excellent job identifying patients at a high risk of developing kidney failure early. The C-statistics,

receiving operator curve, and the area under it (AUC) were close to what has been reported in the

derivation and other validation cohorts (Table 2).

A well-calibrated risk equation's predictions should match the observed risk. At 5 years, the equation

overpredicted the risk for the patients to whom it assigned a risk of 20-50% and underpredicted the risk

in patients to whom it assigned a higher risk (Figure 3); similar findings were also seen in the external

validation of this equation in Chinese, Whites, and South Asians (Table 2)[6–8]. However, the equation

calibration should be studied in a larger population to achieve more robust results.

232 Our study has weaknesses. First, our sample size is significantly smaller than the other populations in 233 which this equation has been validated; therefore, there is uncertainty in our results, and a more 234 extensive study is needed to assess the equation performance in American Indians and Hispanics. We 235 used the bootstrapping technique for the metrics of C-statistics and IPA to obtain robust estimates and 236 confidence intervals. Furthermore, despite of small sample size, the equation discrimination, and 237 calibration performance match what has been reported in the other cohorts (Table 2). Second, our 238 cohort had more severe disease than the equation development and the other cohorts in which it has 239 been validated apart from the South Asian cohort [8], which could be the reason for the poor equation 240 calibration seen in this study and underscores the need for an IgA risk-prediction equation developed in 241 ethnically and racially diverse patients with advanced kidney disease.

242 Herein we provide the first report of IgA risk prediction tool performance in a population from the U.S. 243 Southwest. We performed a rigorous chart review to ensure the accuracy of our data. We modeled the 244 observed and predicted risks on a continuous scale which precluded the creation of arbitrary risk 245 categories. 246 In summary, we showed that IgAN is diagnosed later in New Mexico, which may point towards 247 economic and health care disparities. The international IgAN risk prediction tool without race can 248 accurately and timely identify patients at a high risk of disease progression. In this cohort, the 5-year observed risk was lower in patients assigned a risk estimate of <50% of developing kidney failure and 249 250 higher in patients assigned a risk estimate of >50%; these findings indicate over and under-prediction by 251 the IgA International risk prediction tool, respectively. Our study suggests that the international IgAN 252 risk prediction tool can be used to identify patients who are at a high risk of developing kidney failure; 253 however, the calibration of the international IgAN risk prediction equation in our population was less 254 than optimal and underscores the need of an IgAN risk prediction tool developed in a racially diverse 255 population with more severe disease.

- 256 Disclosures
- 257 Saeed Kamran Shaffi:
- 258 Advisory board: Novartis
- 259
- 260 Christos Argyropoulos:
- 261 Consultant Agreements: Bayer, Baxter, Otsuka, Quanta

- 262 Funding
- 263 Saeed K Shaffi: The University of New Mexico Kidney biopsy registry was established by funding from the
- 264 Dialysis Clinic, Inc.

265 Acknowledgments:

- 266 The authors want to acknowledge the services of University of New Mexico Clinical and Translational
- 267 Science Center (CTSC) who provided support for entering the data in the University of New Mexico
- 268 Kidney biopsy registry. We would specifically like to thank Mr. Hugo A Vilchis and Greg Trejo on working
- 269 on this project.

270 Author Contribution

- 271 Saeed K Shaffi was responsible for funding acquisition for establishing the kidney biopsy registry, study
- 272 conceptualization, project administration, data curation, and writing the original draft.
- 273 Edger Fischer reviewed the kidney biopsies and assigned a MEST-C score.
- 274 Christos Argyropolus devised study methodology and contributed to analysis.
- 275 Brent Wegner advised about project administration, validation and reviewing and editing of the
- 276 manuscript.

277 Data Sharing Statement:

- 278 Restrictions to the data apply; as per the University of New Mexico Institutional Review Board, an IRB
- 279 modification with a data sharing agreement is required to provide data but can be arranged upon
- 280 request.

281 References

282 283	1.	Moran SM, Cattran DC. Recent advances in risk prediction, therapeutics and pathogenesis of IgA nephropathy. Minerva Med. 2019; <i>110:439</i> –449						
284 285	2.	Research C for DE and. FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease. FDA. 2021						
286 287 288	3.	Selvaskandan H, Kay Cheung C, Dormer J, et al. Inhibition of the Lectin Pathway of the Complement System as a Novel Approach in the Management of IgA Vasculitis-Associated Nephritis. Nephron. 2020; <i>144:453</i> –458						
289 290	4.	Sarnak MJ, Amann K, Bangalore S, et al. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019; <i>74:1823</i> –1838						
291 292	5.	Barbour SJ, Coppo R, Zhang H, et al. Evaluating a New International Risk-Prediction Tool in IgA Nephropathy. JAMA Intern Med. 2019; <i>179:942</i> –952						
293 294	6.	Zhang J, Huang B, Liu Z, et al. External Validation of the International IgA Nephropathy Prediction Tool. Clin J Am Soc Nephrol CJASN. 2020; <i>15:1112</i> –1120						
295 296	7.	Zhang Y, Guo L, Wang Z, et al. External Validation of International Risk-Prediction Models of IgA Nephropathy in an Asian-Caucasian Cohort. Kidney Int Rep. 2020; <i>5:1753</i> –1763						
297 298	8.	Bagchi S, Upadhyay AD, Barwad A, et al. The International IgA Nephropathy Network Prediction Tool Underestimates Disease Progression in Indian Patients. Kidney Int Rep. 2022; 7:1210–1218						
299 300	9.	Papasotiriou M, Stangou M, Chlorogiannis D, et al. Validation of the International IgA Nephropathy Prediction Tool in the Greek Registry of IgA Nephropathy. Front Med. 2022;9						
301 302	10.	Smith SM, Tung KSK. Incidence of IgA-related nephritides in American Indians in New Mexico. Hum Pathol. 1985; <i>16</i> :181–184						
303 304	11.	Heus P, Reitsma JB, Collins GS, et al. Transparent Reporting of Multivariable Prediction Models in Journal and Conference Abstracts: TRIPOD for Abstracts. Ann Intern Med. 2020						
305 306	12.	van Geloven N, Giardiello D, Bonneville EF, et al. Validation of prediction models in the presence of competing risks: a guide through modern methods. BMJ. 2022; e069249						
307 308	13.	Kattan MW, Gerds TA. The index of prediction accuracy: an intuitive measure useful for evaluating risk prediction models. Diagn Progn Res. 2018; 2:7						
309 310	14.	Flanagin A, Frey T, Christiansen SL, AMA Manual of Style Committee. Updated Guidance on the Reporting of Race and Ethnicity in Medical and Science Journals. JAMA. 2021; <i>326:621</i> –627						
311 312	15.	New Mexico Report - 2017. Talk Poverty. https://talkpoverty.org/state-year-report/new-mexico- 2017-report/. Accessed 7 Nov 2022						

- 313 16. Earnings Disparities by Race and Ethnicity | U.S. Department of Labor.
- https://www.dol.gov/agencies/ofccp/about/data/earnings/race-and-ethnicity. Accessed 7 Nov
 2022
- 316 17. Promotions C for NM and, Public Information Staff UCB. US Census Bureau 2010 Census.
- 317 http://www.census.gov/2010census/data/. Accessed 22 Apr 2015

318

320 Tables with legends

321 Table 1: Demographic, Clinical, and the Oxford Classification of the patients with IgAN stratified on Race322 and Ethnicity

	Overall , N = 34 ¹	Hispanic, N = 15 ¹	American Indian, N = 9 ¹	Other , N = 10 ²	p-value ²
Age; Median (IQR)	38 (27 - 45)	35 (29 - 47)	40 (26 - 44)	40 (25 - 50)	>0.9
Sex; n(%)					>0.9
Female	18 (53%)	8 (53%)	5 (56%)	5 (50%)	
Male	16 (47%)	7 (47%)	4 (44%)	5 (50%)	
Race; n(%)					<0.001
White	11 (32%)	8 (53%)	0 (0%)	3 (30%)	
American Indian	9 (26%)	0 (0%)	9 (100%)	0 (0%)	
Unknown	6 (18%)	4 (27%)	0 (0%)	2 (20%)	
Asian	3 (8.8%)	0 (0%)	0 (0%)	3 (30%)	
Hispanic	3 (8.8%)	3 (20%)	0 (0%)	0 (0%)	
Other	1 (2.9%)	0 (0%)	0 (0%)	1 (10%)	
Black/African American	1 (2.9%)	0 (0%)	0 (0%)	1 (10%)	
Creatinine (mg/dl); Median (IQR)	2.15 (1.51 - 3 04)	2.10 (1.56 -	2.41 (1.80 -	1.70 (1.40 - 2.75)	0.4
eGFR (ml/min/1.73m2); Median	34 (20 - 51)	34 (22 - 48)	27 (11 - 41)	40 (31 - 56)	0.4
Baseline Proteinuria (g/g); Median	2.7 (1.5 - 5.8)	3.6 (1.6 - 6.1)	3.6 (2.0 - 4.3)	1.6 (1.1 - 2.7)	0.3
Mean Arterial BP (mmHg); Median	99 (89 - 104)	97 (90 - 107)	100 (97 - 103)	95 (85 - 103)	0.5
Immunosuppression around	12 (35%)	6 (40%)	6 (67%)	0 (0%)	0.006
ACEi/ARB around biopsy; n (%)	21 (62%)	9 (60%)	6 (67%)	6 (60%)	>0.9
Primary Outcome; n (%)	23 (68%)	12 (80%)	6 (67%)	5 (50%)	0.3
M; n (%)					0.8
M0	10 (29%)	5 (33%)	3 (33%)	2 (20%)	
M1	24 (71%)	10 (67%)	6 (67%)	8 (80%)	
E; n (%)					>0.9
EO	20 (59%)	9 (60%)	5 (56%)	6 (60%)	
E1	14 (41%)	6 (40%)	4 (44%)	4 (40%)	
S; n (%)					0.049
SO	4 (12%)	0 (0%)	1 (11%)	3 (30%)	
S1	30 (88%)	15 (100%)	8 (89%)	7 (70%)	
T; n (%)					0.5
ТО	1 (2.9%)	1 (6.7%)	0 (0%)	0 (0%)	
T1	24 (71%)	9 (60%)	6 (67%)	9 (90%)	
T2	9 (26%)	5 (33%)	3 (33%)	1 (10%)	
C; n (%)					0.8
CO	22 (65%)	10 (67%)	5 (56%)	7 (70%)	
C1	12 (35%)	5 (33%)	4 (44%)	3 (30%)	

324Table 2: Summary of the studies assessing the performance of the international IgAN risk prediction tool in
325various populations

	N	Population characteristic	Follow-up duration and use	Creatinine; median (IQR)	Proteinuria; median (IQ R)	*R2D	[∞] AUC at 5 years ΩC-statistics	Calibration slope	Comments
Barbour et al; 2019: Derivation	2781	Predominantly White, Chinese, or Japanese (in that order)	4.8 (3.0– 7.6)	1.0 (0.8–1.4)	1.2 (0.7–2.2)	25.3	0.81		
Barbour et al; 2019: Validation	1146	Predominantly Japanese, Chinese or White (in that order)	5.8 (3.4– 8.5	1.0 (0.8–1.3)	1.3 (0.6–2.4)	35.3	0.81	1.19 (1.04-1.34)	Excellent discrimination Good calibration
J Zhang et al; 2020	1373	Chinese	2.4 (1.8– 3.6)	1.0 (0.8–1.4)	1.7 (0.9–3.3)		0.862	1.30 (1.15–1.45)	Excellent discrimination The model modestly underestimated the risk
Y Zhang et al; 2020	1275	Primarily Chinese with a few Argentinian	4.8 (3.0– 7.6)	1.04 (0.80– 1.4)	1.2 (0.7–2.2)	37.6	0.81	0.87 (0.73–1.0)	Excellent discrimination Acceptable calibration for the prediction model without race
Bagchi et al: 2022	316	South Asian		Cr not reported	2.6 (1.5–4.0)	49.9	0.819	1.21 (0.95–1.47)	Excellent discrimination The model underestimated the trajectory of disease progression across all risk groups
Papasotiriou et al; 2022	264	Greek	8.5 (5- 10.83)	1.2 (0.9–1.8)	Not reported: 41% of the patients had a proteinuria of ≤1 gram per day	35	0.70	0.40	Acceptable discrimination
*R2D R-squared as Deviance, [∞] AUC Area under the cure, Ω C-statistics Concordance Statistics									

327Table 3: Numerical summary of the measures of the International IgAN Risk Prediction Tool without race 328performance in our cohort

Discrimination					
Metric	Value				
C-Statistics at 5 years	0.79 (0.64 – 0.91)				
Area Under the Curve at 5 years	0.79 (0.68 – 0.89)				
Calibration					
Observed/Estimated Risk at 5 years (O/E)	0.88 (0.51 – 1.25)				
Calibration Intercept	0.10 (-0.37 – 0.58)				
Calibration Slope	3.03 (0.43 – 5.64)				
Overall Prediction Error					
Index of Prediction Accuracy (IPA)	0.33 (0.02 -0.50)				

330 Figure legends

- 331 Figure 1: Flow diagram showing the patients identified, excluded, and included in the study
- Figure 2: Receiver operator curve (ROC) at 5-years of the International IgAN risk prediction tool in the study population.
- Figure 3: Calibration curve (Estimated risks plotted against Observed risk) at 5 years of the International
- 335 IgAN risk prediction equation in the study population. Values below and above the 45 degrees line
- 336 signify over and underprediction, respectively. The rug plot shows the distribution of the estimated
- 337 risks.



Figure 1: Flow diagram showing the patients identified, excluded, and included in the study



Figure 2: Receiver operator curve (ROC) at 5-years of the International IgAN risk prediction tool in the study population.



Figure 3: Calibration curve (Estimated risks plotted against Observed risk) at 5 years of the International IgAN risk prediction equation in the study population. Values below and above the 45 degrees line signify over and underprediction, respectively. The rug plot shows the distribution of the estimated risks.